“Dravet Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dravet Syndrome Market.
The Dravet Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Dravet Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Dravet Syndrome and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dravet Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage products (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
-
NAV1.1 voltage-gated sodium channel modulators
-
Vitamin K replacements
-
Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
-
Serotonin 2C receptor agonists
-
NAV1.1 voltage-gated sodium channel modulators; RNA interference
-
GABA A receptor agonists
-
Serotonin receptor modulators
-
TYK2 kinase inhibitors
Learn How the Ongoing Clinical & Commercial Activities will Affect the Dravet Syndrome Therapeutic Segment @
https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight
Dravet Syndrome Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for Dravet Syndrome. Currently, Takeda is leading the therapeutics market with its Dravet Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Players in the Dravet Syndrome Therapeutics Market Include:
-
Biocodex
-
Eisai
-
Encoded Therapeutics
-
Epygenix Therapeutics
-
GW Pharmaceuticals
-
Longboard Pharmaceuticals
-
Ovid Therapeutics
-
PTC Therapeutics
-
Stoke Therapeutics
-
Takeda
-
Virpax Pharmaceuticals
-
Zogenix
And Many Others
Dravet Syndrome Emerging and Marketed Drugs Covered in the Report Include:
-
EPX-100: Epygenix Therapeutics
-
STK-001: Stoke Therapeutics
-
LP352: Longboard Pharmaceuticals
-
BMB 101: Bright Minds Biosciences
-
NT102: Neuroene Therapeutics
-
STK 001: Stoke Therapeutics
-
Diazepam : XERIS Pharmaceuticals
-
Lorcaserin: Eisai Inc
-
Soticlestat: Takeda
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Dravet Syndrome Current Treatment Patterns
4. Dravet Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Dravet Syndrome Late Stage Products (Phase-III)
7. Dravet Syndrome Mid-Stage Products (Phase-II)
8. Dravet Syndrome Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dravet Syndrome Discontinued Products
13. Dravet Syndrome Product Profiles
14. Key Companies in the Dravet Syndrome Market
15. Key Products in the Dravet Syndrome Therapeutics Segment
16. Dormant and Discontinued Products
17. Dravet Syndrome Unmet Needs
18. Dravet Syndrome Future Perspectives
19. Dravet Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Explore the Key Offerings of the Report
https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/